inclusion criteria: * subjects \> 60 years of age * diagnosed case (pcr test for covid-19 if available) or covid-19 clinical symptoms (defined as fever, dry cough, dyspnea, chest radiography with compatible findings with covid-19) * lymphocyte count ≥ 0.2 x 103/µl and ≤1.0 x 103/µl. * neutrophil count ≥ 1.8 x 103/µl, platelets ≥ 150 x 103/µl. * rox ≥ 10 index * signed informed consent document * willing to comply with the lenalidomide risk minimization program (pregnancy prevention program approved)

inclusion criteria: * subjects \> 60 years of age * diagnosed case (pcr test for covid-19 if available) or covid-19 clinical symptoms (defined as fever, dry cough, dyspnea, chest radiography with compatible findings with covid-19) * lymphocyte count ≥ 0.2 x 103/µl and ≤1.0 x 103/µl. * neutrophil count ≥ 1.8 x 103/µl, platelets ≥ 150 x 103/µl. * rox ≥ 10 index * signed informed consent document * willing to comply with the lenalidomide risk minimization program (pregnancy prevention program approved)

inclusion criteria: - subjects > 60 years of age - diagnosed case (pcr test for covid-19 if available) or covid-19 clinical symptoms (defined as fever, dry cough, dyspnea, chest radiography with compatible findings with covid-19) - lymphocyte count ≥ 0.2 x 103/µl and ≤1.0 x 103/µl. - neutrophil count ≥ 1.8 x 103/µl, platelets ≥ 150 x 103/µl. - rox ≥ 10 index - signed informed consent document - willing to comply with the lenalidomide risk minimization program (pregnancy prevention program approved)

inclusion criteria: - subjects > 60 years of age - diagnosed case (pcr test for covid-19 if available) or covid-19 clinical symptoms (defined as fever, dry cough, dyspnea, chest radiography with compatible findings with covid-19) - lymphocyte count ≥ 0.2 x 103/µl and ≤1.0 x 103/µl. - neutrophil count ≥ 1.8 x 103/µl, platelets ≥ 150 x 103/µl. - rox ≥ 10 index - signed informed consent document - willing to comply with the lenalidomide risk minimization program (pregnancy prevention program approved)